Yan Xu Selected Research

enterohemolysin

12/2022

Dual role of CsrA in regulating the hemolytic activity of Escherichia coli O157:H7.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yan Xu Research Topics

Disease

331	Neoplasms (Cancer) 11/2022 - 02/2002
77	Infections 07/2022 - 04/2004
70	Inflammation (Inflammations) 09/2022 - 09/2003
52	Neoplasm Metastasis (Metastasis) 03/2022 - 01/2005
47	Breast Neoplasms (Breast Cancer) 10/2022 - 07/2006
42	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022 - 04/2010
39	Carcinogenesis 05/2022 - 02/2002
33	Fibrosis (Cirrhosis) 09/2022 - 01/2008
29	Stomach Neoplasms (Stomach Cancer) 10/2022 - 01/2008
29	Lung Neoplasms (Lung Cancer) 10/2022 - 08/2007
29	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 03/2002
28	Multiple Myeloma 01/2021 - 05/2007
24	Hypoxia (Hypoxemia) 01/2022 - 10/2002
23	Hepatocellular Carcinoma (Hepatoma) 09/2022 - 05/2007
22	Adenocarcinoma 05/2022 - 02/2002
22	Wounds and Injuries (Trauma) 01/2022 - 11/2003
21	Pain (Aches) 10/2021 - 12/2007
20	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2003
20	Stroke (Strokes) 01/2021 - 04/2011
19	Adenocarcinoma of Lung 01/2022 - 04/2010
18	Ischemia 01/2022 - 04/2005
18	Pneumonia (Pneumonitis) 01/2022 - 02/2003
17	COVID-19 01/2022 - 01/2020
17	Leukemia 01/2020 - 10/2007
16	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 01/2017
16	Carcinoma (Carcinomatosis) 01/2020 - 02/2002
15	Ischemic Stroke 05/2022 - 08/2010
14	Body Weight (Weight, Body) 09/2022 - 01/2013
14	Hemorrhage 03/2022 - 11/2005
14	Periodontitis 01/2022 - 09/2003
14	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2002
13	Obesity 05/2022 - 08/2011
13	Acute Kidney Injury (Acute Renal Failure) 04/2022 - 06/2008
13	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2010
13	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 11/2004
13	Disease Progression 01/2022 - 02/2013
13	Lymphatic Metastasis 01/2021 - 05/2010
13	Dyskinesias (Dyskinesia) 01/2021 - 01/2003
12	Liver Cirrhosis (Hepatic Cirrhosis) 09/2022 - 02/2009
12	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2022 - 06/2002
12	Sepsis (Septicemia) 04/2022 - 03/2014
12	Hypertension (High Blood Pressure) 02/2022 - 10/2003
12	Infarction (Infarctions) 01/2020 - 03/2002
11	Ulcerative Colitis 07/2022 - 02/2002
11	Virus Diseases (Viral Diseases) 01/2022 - 08/2002
11	Melanoma (Melanoma, Malignant) 01/2022 - 04/2006
11	Colonic Neoplasms (Colon Cancer) 05/2020 - 07/2002
10	Reperfusion Injury 08/2022 - 08/2005

Drug/Important Bio-Agent (IBA)

126	Proteins (Proteins, Gene)FDA Link 05/2022 - 09/2002
68	Biomarkers (Surrogate Marker)IBA 12/2022 - 02/2002
60	Pharmaceutical PreparationsIBA 05/2022 - 09/2005
43	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 03/2002
41	Biological ProductsIBA 10/2022 - 03/2002
41	MicroRNAs (MicroRNA)IBA 04/2022 - 10/2010
38	CytokinesIBA 10/2022 - 10/2003
29	Long Noncoding RNAIBA 10/2022 - 09/2014
28	LipidsIBA 09/2022 - 04/2004
27	Messenger RNA (mRNA)IBA 01/2022 - 01/2003
23	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 06/2011
23	RNA (Ribonucleic Acid)IBA 03/2022 - 12/2003
22	Transcription Factors (Transcription Factor)IBA 01/2022 - 07/2004
22	ErbB Receptors (EGF Receptor)IBA 01/2022 - 02/2004
21	Therapeutic UsesIBA 01/2022 - 04/2005
20	Antiviral Agents (Antivirals)IBA 09/2022 - 02/2010
18	lysophosphatidic acidIBA 10/2019 - 09/2002
17	AntibodiesIBA 07/2022 - 01/2008
17	LigandsIBA 01/2022 - 11/2009
16	CateninsIBA 04/2022 - 01/2012
15	EnzymesIBA 10/2022 - 03/2003
15	CholesterolIBA 05/2022 - 10/2010
15	Immune Checkpoint InhibitorsIBA 04/2022 - 02/2017
15	Hemoglobins (Hemoglobin)IBA 04/2022 - 04/2008
15	Oxygen (Dioxygen)IBA 03/2022 - 08/2009
15	Small Interfering RNA (siRNA)IBA 01/2022 - 09/2006
15	Peptides (Polypeptides)IBA 01/2022 - 04/2010
15	Surface-Active Agents (Surfactants)IBA 01/2021 - 09/2003
14	AnticoagulantsIBA 01/2022 - 09/2013
14	AntigensIBA 01/2022 - 07/2006
14	Tyrosine Kinase InhibitorsIBA 12/2021 - 04/2010
14	Phosphotransferases (Kinase)IBA 01/2021 - 09/2002
14	Bortezomib (Velcade)FDA Link 01/2021 - 06/2008
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2022 - 12/2004
13	Interleukin-6 (Interleukin 6)IBA 09/2022 - 10/2003
13	Indicators and Reagents (Reagents)IBA 01/2022 - 04/2006
13	VaccinesIBA 01/2021 - 08/2002
12	Caspase 3 (Caspase-3)IBA 08/2022 - 09/2002
12	Monoclonal AntibodiesIBA 01/2022 - 03/2005
11	Paclitaxel (Taxol)FDA LinkGeneric 05/2022 - 09/2002
11	LipopolysaccharidesIBA 05/2022 - 07/2007
11	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 09/2013
11	Levodopa (L Dopa)FDA LinkGeneric 01/2021 - 01/2003
11	CalciumIBA 08/2020 - 09/2006
10	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 03/2022 - 05/2002

Therapy/Procedure

179	Therapeutics 10/2022 - 03/2002
63	Drug Therapy (Chemotherapy) 08/2022 - 11/2005
33	Immunotherapy 05/2022 - 04/2010
18	Radiotherapy 01/2022 - 11/2011
12	Chinese Traditional Medicine (Traditional Chinese Medicine) 06/2022 - 03/2010
12	Lasers (Laser) 01/2022 - 03/2002
11	Aftercare (After-Treatment) 03/2021 - 03/2002